临床药师参与弥漫大B细胞淋巴瘤患者抗乙型肝炎病毒治疗的药学实践

摘要

OBJECTIVE:To investigate the drug selection and pharmaceutical care for patients with diffuse large B -cell lymphoma in anti-hepatitis B virus ( HBV) therapy .METHODS:The clinical pharmacists participated and evaluated the treatment process of anti-HBV therapy in diffuse large B-cell lymphoma patient .By referring to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology:Non-hodgkin Lymphoma and Expert Consensus of Special Antiviral Treatment in Patients with Chronic Hepatitis B:2014 and the related literatures , the clinical pharmacists formulated rational anti-HBV medication regimens .RESULTS: Combined with the patients ’practical conditions , the clinical pharmacists advised the clinicians to use Entecavir tablets as anti -HBV medication and provided pharmaceutical care for patients according to the guidelines and expert consensus , so as to avoid HBV reactivation and explosive hepatitis B and promote the smooth completion of chemotherapy .CONCLUSIONS: The clinical pharmacists must pay more attention to the motoring of HBV in patients with diffuse large B-cell lymphoma , choose correct and rational anti-HBV to promote the smooth completion of chemotherapy , so as to ensure the safe and effective medication .%目的：了解弥漫大B细胞淋巴瘤患者抗乙型肝炎病毒（hepatitis B virus，HBV）治疗的用药选择及药学监护。方法：介绍临床药师参与1例弥漫大B细胞淋巴瘤合并乙型肝炎病毒感染患者的抗病毒治疗过程，参考《美国国家综合癌症网络肿瘤学临床实践指南：非霍奇金淋巴瘤》《慢性乙型肝炎特殊患者抗病毒治疗专家共识：2014年》和相关文献，制订合理的抗HBV药物治疗方案。结果：结合患者的实际情况，临床药师依据指南和专家共识，建议临床医师选择恩替卡韦片作为患者抗HBV治疗用药，并对患者进行药学监护，避免了HBV再激活和爆发性乙型病毒性肝炎的发生，促进了化疗顺利完成。结论：恶心淋巴瘤患者化疗前应密切关注HBV的监测，正确、合理地选择抗HBV药，有利于促进化疗的顺利完成，保证用药安全、有效。